9 January 2020
Oxford BioTherapeutics Initiates Dose-Escalation Portion of U.S. Phase I Clinical Trial for OBT076 in Patients with Advanced Solid Tumors
Dose-escalation starting at a dose based on results from a European study sponsored by partner, Menarini Ricerche. Phase I program includes two U.S. expansion cohorts: (1) High risk cohort of HER2 negative, Hormone receptor positive (HER2-/HR+) chemotherapy-failure breast...
8 January 2020
Cytox appoints Ian Gilham as new Chairman of the Board
8th January 2020: Oxford & Manchester, UK. Cytox Ltd, which provides non-invasive, risk assessment and patient stratification tools for Alzheimer's disease and dementia, has appointed Dr Ian Gilham as the new Chairman of the Board. Dr Gilham, who brings significant...